HR 2821
119th Congress
House
Health
Administrative law and regulatory procedures
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Medical research
Research administration and funding
FDA Modernization Act 3.0
Everywhere this bill has been
14 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 20, 2026 · 2:57 PM EDT
Motion to reconsider laid on the table Agreed to without objection.
Jul 20, 2026 · 2:57 PM EDT
On motion to suspend the rules and pass the bill Agreed to by voice vote.
Jul 20, 2026 · 2:47 PM EDT
DEBATE - The House proceeded with forty minutes of debate on H.R. 2821.
Jul 20, 2026 · 2:47 PM EDT
Considered under suspension of the rules.
Jul 20, 2026 · 2:47 PM EDT
Mr. Guthrie moved to suspend the rules and pass the bill. H.R. 2821 — "To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods."
Jun 18, 2026
Placed on the Union Calendar, Calendar No. 614.
Jun 18, 2026
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
May 21, 2026
Committee Consideration and Mark-up Session Held
May 21, 2026
Ordered to be Reported by the Yeas and Nays: 44 - 0.
May 13, 2026
Forwarded by Subcommittee to Full Committee by Voice Vote.
May 13, 2026
Subcommittee Consideration and Mark-up Session Held
Apr 10, 2026
Referred to the Subcommittee on Health.
Apr 10, 2025
Introduced in House
Apr 10, 2025
Referred to the House Committee on Energy and Commerce.
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
What's happening now
Motion to reconsider laid on the table Agreed to without objection.
Related & companion bills
1
Bill text
3 versions
- Engrossed in House Formatted Text PDF Formatted XML
- Introduced in House Formatted Text PDF Formatted XML
- Reported in House Formatted Text PDF Formatted XML
Committees of jurisdiction
2
Cosponsors
41
D
Thanedar, Shri
R
Langworthy, Nicholas A.
R
Kim, Young
D
Johnson, Julie
R
Kean, Thomas H.
D
Krishnamoorthi, Raja
D
Neguse, Joe
R
Weber, Randy K. Sr.
R
Lawler, Michael
D
Pocan, Mark
D
Vindman, Eugene Simon
R
Calvert, Ken
R
Lee, Laurel M.
R
Bilirakis, Gus M.
R
Fitzgerald, Scott
D
Frankel, Lois
D
Harder, Josh
R
Valadao, David G.
D
Norton, Eleanor Holmes
R
Salazar, Maria Elvira
R
Smith, Christopher H.
R
Tenney, Claudia
D
Lieu, Ted
D
Crow, Jason
D
Gottheimer, Josh
R
Obernolte, Jay
D
Chu, Judy
D
Goldman, Daniel S.
D
Scholten, Hillary J.
D
Soto, Darren
R
Carey, Mike
R
Crenshaw, Dan
R
Fitzpatrick, Brian K.
R
Malliotakis, Nicole
D
Nadler, Jerrold
D
Doggett, Lloyd
D
Barragán, Nanette Diaz
R
Buchanan, Vern
D
Carter, Troy A.
D
DeLauro, Rosa L.
R
Harshbarger, Diana
Cite this page
U.S. Congress. (2026). H.R. 2821: FDA Modernization Act 3.0. 119th Congress. Open America. https://openamerica.io/bill/119-HR-2821/
"H.R. 2821: FDA Modernization Act 3.0." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-2821/.
H.R. 2821, 119th Cong. (2026), https://openamerica.io/bill/119-HR-2821/.
[H.R. 2821: FDA Modernization Act 3.0](https://openamerica.io/bill/119-HR-2821/)